Belimumab (3) – Benlysta®
Lupus nephritis
Characteristics
| Start date | 15.05.2021 |
|---|---|
| Resolution | 01.07.2021 |
| INN | Belimumab |
| Brand name | Benlysta® |
| Pharm. company | GlaxoSmithKline GmbH & Co. KG |
| G-BA Procedure ID | D-682 |
| ATC code | L04AA26 Selective immunosuppressants (L04AA) |
| DDD | 25 mg O |
| Therapeutic area | Musculoskeletal system diseases Systemic lupus erythematosus (SLE) |
| Reason for procedure | not completed: discontinued |
Associated procedures
| Belimumab (3) | Benlysta® | GlaxoSmithKline GmbH & Co. KG | Lupus nephritis | n.d. | discontinued | |
| Belimumab (2) | Benlysta® | GlaxoSmithKline GmbH & Co. KG | Systemic lupus erythematosus | 30–550 | 100% Hint for non-quantifiable additional benefit | |
| Belimumab (1) | Benlysta® | GlaxoSmithKline GmbH & Co. KG | Systemic lupus erythematosus | 7,000 | 100% Indication of considerable additional benefit |
<< List of all resolutions